Myriad Genetics (NASDAQ:MYGN) Research Coverage Started at Craig Hallum

Craig Hallum began coverage on shares of Myriad Genetics (NASDAQ:MYGN) in a research report sent to investors on Wednesday, MarketBeat Ratings reports. The firm issued a buy rating and a $29.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. Leerink Partners cut shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $30.00 to $21.00 in a research note on Monday, December 9th. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Piper Sandler dropped their price objective on Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, January 30th. StockNews.com upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. Finally, Stephens reaffirmed an “equal weight” rating and set a $20.00 price target on shares of Myriad Genetics in a report on Thursday, January 16th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Myriad Genetics has a consensus rating of “Hold” and an average price target of $22.54.

Myriad Genetics Stock Down 0.6 %

MYGN stock opened at $14.56 on Wednesday. Myriad Genetics has a twelve month low of $12.04 and a twelve month high of $29.30. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -11.20 and a beta of 1.88. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $13.46 and a two-hundred day moving average price of $20.01.

Hedge Funds Weigh In On Myriad Genetics

A number of hedge funds have recently added to or reduced their stakes in MYGN. Vanguard Group Inc. grew its holdings in shares of Myriad Genetics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company’s stock worth $145,203,000 after purchasing an additional 279,379 shares in the last quarter. State Street Corp increased its holdings in Myriad Genetics by 8.3% in the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after buying an additional 359,685 shares during the period. Earnest Partners LLC raised its position in shares of Myriad Genetics by 0.4% in the 4th quarter. Earnest Partners LLC now owns 3,971,598 shares of the company’s stock valued at $54,451,000 after buying an additional 15,650 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Myriad Genetics by 13.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,766,729 shares of the company’s stock worth $37,932,000 after acquiring an additional 336,770 shares during the period. Finally, Disciplined Growth Investors Inc. MN boosted its position in shares of Myriad Genetics by 21.1% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after acquiring an additional 440,107 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.